Please use this identifier to cite or link to this item: http://ir.swu.ac.th/jspui/handle/123456789/14023
Title: A randomized controlled trial of chelated zinc for prevention of the common cold in thai school children
Authors: Rerksuppaphol S.
Rerksuppaphol L.
Keywords: antibiotic agent
placebo
qualimed
unclassified drug
zinc bisglycinate
zinc derivative
absence of side effects
absenteeism
adolescent
antibiotic therapy
article
child
common cold
controlled study
coughing
diarrhea
disease duration
double blind procedure
drug efficacy
female
fever
human
incidence
male
normal human
randomized controlled trial
rhinorrhea
school child
taste disorder
Thailand
vomiting
winter
Adolescent
Chemoprevention
Child
Common Cold
Double-Blind Method
Female
Glycine
Humans
Incidence
Male
Placebos
Schools
Thailand
Treatment Outcome
Issue Date: 2013
Abstract: Background: The common cold is responsible for the largest proportion of school and work absenteeism and is a huge economic burden. None of the currently available interventions is clearly effective for prevention or treatment. Objective: To assess the efficacy of 15-mg chelated zinc (zinc bis-glycinate) given once a day for 3 months during the winter season to healthy school children aged 8-13 years to prevent symptoms of the common cold. Methods: In a double-blind randomized controlled trial, zinc bis-glycinate 15 mg or matching placebo once a day for 3 months was administered to healthy school children aged 8-13 years. Primary outcomes were any symptom of cold (fever, cough, rhinorrhoea) during the study period, and secondary outcomes were vomiting, diarrhoea, use of antibiotics, school absence for any reason, school absence because of a cold and duration of all symptoms. Results: Of 50 children in each group, 42 (84%) in the zinc group and 41 (82%) in the placebo group (P=1.00) developed at least one symptom of a cold. There was no difference in the incidence of fever, cough, rhinorrhoea, school absence and school absence related to the common cold compared with children in the placebo group. However, duration of cough [median (IQR) 1.0 (0.0-6.0) vs 6.0 (0.0-13.3) days], rhinorrhoea [median (IQR) 2.0 (0.0-7.0) vs 5.5 (1.0-15.3) days] and the frequency of having two or more symptoms of the common cold [median (IQR) 0.0 (0.0-1.0) vs 1.0 (0.0-5.3) days] were reduced significantly in the intervention group (P<0.01). Conclusions: Zinc bis-glycinate given in a dose of 15 mg once a day for 3 months failed to reduce the incidence of the common cold in 8 to 13-year-old school children, but decreased the number of days on which children suffered from cough, rhinorrhoea and the likelihood of having two or more symptoms of the common cold. © W. S. Maney & Son Ltd 2013.
URI: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84881483563&doi=10.1179%2f2046905513Y.0000000064&partnerID=40&md5=24e346d137dbee8c26b0051326387f1b
http://ir.swu.ac.th/jspui/handle/123456789/14023
ISSN: 20469047
Appears in Collections:SCOPUS 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.